Neurocrine Biosciences (NASDAQ:NBIX) Hits New 12-Month High at $119.65

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $119.65 and last traded at $118.50, with a volume of 631327 shares changing hands. The stock had previously closed at $117.64.

Several research analysts have weighed in on NBIX shares. TheStreet raised Neurocrine Biosciences from a “c+” rating to a “b” rating in a research report on Tuesday, November 19th. Piper Jaffray Companies boosted their price objective on Neurocrine Biosciences from $111.00 to $116.00 in a research report on Tuesday, November 5th. ValuEngine cut Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Zacks Investment Research cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $105.72.

The stock has a market capitalization of $10.74 billion, a P/E ratio of 538.95, a price-to-earnings-growth ratio of 5.90 and a beta of 1.24. The company has a 50 day simple moving average of $106.73 and a 200-day simple moving average of $94.00. The company has a debt-to-equity ratio of 0.83, a current ratio of 7.08 and a quick ratio of 6.99.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, November 4th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). The firm had revenue of $222.09 million during the quarter, compared to the consensus estimate of $211.31 million. Neurocrine Biosciences had a net margin of 3.12% and a return on equity of 5.67%. The business’s quarterly revenue was up 46.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.52 earnings per share. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 0.82 earnings per share for the current fiscal year.

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $110.01, for a total value of $1,100,100.00. Following the sale, the insider now directly owns 26,728 shares in the company, valued at $2,940,347.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Julie Cooke sold 987 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $88.56, for a total value of $87,408.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,776 shares of company stock worth $4,936,638. Corporate insiders own 4.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Capital Investment Advisory Services LLC bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at $43,000. NEXT Financial Group Inc raised its stake in shares of Neurocrine Biosciences by 89.8% during the 2nd quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock valued at $47,000 after purchasing an additional 265 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Neurocrine Biosciences by 70.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock valued at $51,000 after purchasing an additional 246 shares during the period. Flagship Harbor Advisors LLC bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at $67,000. Finally, Golden State Wealth Management LLC raised its stake in shares of Neurocrine Biosciences by 100.0% during the 2nd quarter. Golden State Wealth Management LLC now owns 1,000 shares of the company’s stock valued at $84,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 97.13% of the company’s stock.

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Further Reading: Consumer behavior in bull markets

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.